Company intelligence / Profile preview

Cardeas Pharma Corp.

Seattle, Washington, United Statesbiopharmguy.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Cardeas Pharma developed inhaled antibiotic therapies for serious hospital-acquired respiratory infections using a proprietary nebulizer system. Clinical studies included completed Phase 1 and Phase 2 trials evaluating the safety and efficacy of aerosolized amikacin/fosfomycin combinations delivered via the eFlow system to both healthy volunteers and mechanically ventilated patients. Some later-stage clinical programs were withdrawn or not advanced further as of last updates.[1][3][6]

Therapeutic areas: Infectious Diseases
Modalities: Inhaled antibiotics (combination of small molecules)
Industry: Biotech

Drug pipeline

1 asset

amikacin + fosfomycin

Phase 2

Indications: Hospital-acquired pneumonia, Ventilator-associated pneumonia

Beyond the preview

Go deeper on Cardeas Pharma Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardeas Pharma Corp..

Explore the full profile